mabl的动态

Gulf sovereign wealth funds are continuing to consolidate assets, grouping them into platforms to become regional and global champions. ADQ has consolidated its life science assets into a new platform, Arcera, which seeks to align with #AbuDhabi Economic Vision 2030. The value of the new #pharma company exceeds US$2 billion, based on Global SWF data, and is likely to grow rapidly ahead of an IPO - potentially next year. Global SWF takes a look at Arcera's building blocks and what lessons it may take from ADQ's consolidated healthcare platform, PureHealth, which listed in December: https://lnkd.in/ePvU4xiB

As we turn the page into a new chapter, EGMG is ready to take you further than ever before. We are evolving, and focused on pushing the boundaries of what’s possible. Together, let's move forward.?? ?? #EGMG #WeMoveYou #Transformation #Newachapter #MoveForward

It is always a pleasure to be presenting in a conference, and the more pleasure to introduce a topic I am fascinated about. Thank you everyone for listening and sharing your questions and comments, and bearing with my enthusiastic data process views also post-presentation by coffee and cocktails ?? Thank you for invitation #farmasianoppimiskeskus to #myyntilupaseminaari #mls2024 #pms #productmanagementservices #spor #idmp #xevmpd #pharmalex #regulatoryinformatics #regulatoryaffairs

Curious about industry-academia partnerships? Daniel Bradbury, former CEO of Amylin Pharmaceuticals, shares his insights on collaborating with KGI's Team Master's Project (TMP). Our TMP offers life science companies a unique opportunity to drive innovation and tackle real-world challenges. In this video, Bradbury discusses: ?? Exploring new product forms and manufacturing processes ?? Working with interdisciplinary student teams ?? Cost-effective innovation in life sciences ?? Long-term impact on company initiatives "The value that [the students] have created in such a short period of time is tremendous," says Bradbury. Watch to learn how one TMP led to a new product development team at Amylin: https://kgi.link/xvu #LifeSciences #Innovation #KeckGrad #Testimonials

Complete Response Letter Atara Biotherapeutics, Inc. Key Points:Atara Biotherapeutics received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for EBVALLO? (tabelecleucel) to treat post-transplant lymphoproliferative disease (PTLD). The CRL did not cite any deficiencies related to the clinical efficacy or safety of EBVALLO?. Importantly, the FDA did not request any additional clinical trials to support approval. https://lnkd.in/ecyaT-wu

?? TODAY! ?? Join Christian Zeine, Henry Foddy and Margaret Maziarz for a discussion on pharmaceutical impurity analysis. Over 1500 registrants already for this FREE webinar. If you have not registered yet, there is still time - we are starting at 1 pm ET today! #impurityprofiling #pharma

Glimpses from the Why Summit - 23rd American Pharma and Biotech Project, Program and Portfolio Management Conference! ??? From our CEO Sandeep Kumar's insightful session on "???????????????????????? ????????-????-???????????? ???? ???????????? ??????: ?????? ???????? ???? ???? ???? ?????????????? ????????????????????" to an enriching panel discussion, the conference was brimming with innovation and inspiration. ???? Watch the recap! ?? Sandeep Kumar | Sanket Khinvasara #PharmaNPD #InnovationLeadership #Kytes #KytesPSA #Boston

If you are in the #Antwerp #Belgium this week, please join my speaking session representing HiveMQ at the Asset Performance conference at Flanders Expo on the Benefits of open standards like #MQTT and frameworks like #UNS in enhancing #APM.

Magic happens when strategy and execution align. Together, they turn ideas into impact and goals into growth. Looking forward to see the impact this Strategy Workshop will deliver in Q4 ??

@Catailyst, Inc. Trending Topics: Sangamo Therapeutics, Inc. Therapeutics Announces Alignment With FDA on Accelerated Approval Pathway for ST-920 in #Fabry Disease With BLA Submission Expected in 2025 https://lnkd.in/d-HxtncX FDA confirms that estimated glomerular filtration rate (eGFR) slope data at one year across all Phase 1/2 patients can serve as primary basis for approval under Accelerated Approval pathway #Timeline Data supporting Accelerated Approval pathway available in first half of 2025 BLA submission expected in the second half of 2025. #Healthcare #FDA #Biotechnology #Fabry